Biblio
Rituximab is highly effective for pure red cell aplasia and post-transplant lymphoproliferative disorder after unrelated hematopoietic stem cell transplantation. Contemp Oncol (Pozn). 2012;16(3):215-217.
. .
Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients. Cancers (Basel). 2023;15(17).